Nektar Therapeutics Data from REZOLVE-AD Study Accepted for Late-Breaking Oral Presentation

Nektar Therapeutics (NASDAQ:NKTR) is one of the hot stocks to buy with huge upside potential. On October 22, Nektar Therapeutics announced that new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin was accepted for a late-breaking oral abstract presentation. Rezpegaldesleukin is an IL-2 pathway agonist and regulatory T-cell/Treg proliferator being investigated for the treatment of atopic dermatitis.

The REZOLVE-AD Phase 2b study enrolled 393 patients with moderate-to-severe AD who had no prior treatment with biologic or JAK inhibitor therapies. Patients were enrolled across ~110 sites globally. The study’s primary endpoint is the mean improvement in EASI score at the end of the 16-week induction period.

Nektar Therapeutics Data from REZOLVE-AD Study Accepted for Late-Breaking Oral Presentation

Rezpegaldesleukin is a potential first-in-class resolution therapeutic wholly owned by Nektar Therapeutics, which is focused on addressing the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. The drug is a novel, first-in-class regulatory T cell stimulator being developed as a self-administered injection for multiple autoimmune and inflammatory conditions, including atopic dermatitis, which affects ~30 million people in the US.

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company that discovers and develops therapies that selectively modulate the immune system to treat autoimmune disorders in the US and internationally.

While we acknowledge the potential of NKTR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NKTR and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.